Torabizadeh Zhila, Nosrati Anahita, Tahvildari Shadi
Gut and Liver Research Center & Department of Pathology, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Pathology, Mazandaran University of Medical Science, Sari, Iran.
Middle East J Dig Dis. 2016 Jan;8(1):24-30. doi: 10.15171/mejdd.2016.03.
BACKGROUND Some recent studies reported human epidermal growth factor receptor (HER-2/neu) as a marker that can be used in immunological studies of colorectal carcinoma for predicting the prognosis and the treatment. Therefore, we aimed to investigate the frequency of HER-2 expression in patients with colorectal cancer, and explore the relationship between clinicopathological prognostic factors and its expression based on immunohistochemical analysis. METHODS This study included 50 patients with a histologically proven diagnosis of colorectal carcinoma who received surgery at Imam Khomeini Hospital affiliated to Mazandaran University of Medical Sciences. First, HER-2/neu protein expressions were detected by immunohistochemistry and then the data extracted from recorded files. RESULTS The median age of the patients was 60.2±13.9 years (range: 25-93 years). There was no significant relationship between size of tumor, age, sex, lymph node metastases, distant metastasis, differentiation, and stage of the disease with positive expression of HER-2 in this study. CONCLUSION No significant relationship between expression of HER-2 and clinicopathological prognostic factors was found in our study. Further comprehensive and prospective trial with standard method to evaluate the role of HER-2 expression among patients with colorectal cancer is needed.
背景 一些近期研究报道，人表皮生长因子受体（HER-2/neu）可作为一种标志物，用于结直肠癌的免疫学研究，以预测预后和指导治疗。因此，我们旨在通过免疫组织化学分析，研究结直肠癌患者中HER-2表达的频率，并探讨临床病理预后因素与其表达之间的关系。方法 本研究纳入了50例在马赞德兰医科大学附属伊玛目霍梅尼医院接受手术治疗、经组织学确诊为结直肠癌的患者。首先，通过免疫组织化学检测HER-2/neu蛋白表达，然后从记录文件中提取数据。结果 患者的中位年龄为60.2±13.9岁（范围：25 - 93岁）。本研究中，肿瘤大小、年龄、性别、淋巴结转移、远处转移、分化程度及疾病分期与HER-2阳性表达之间均无显著关系。结论 在我们的研究中，未发现HER-2表达与临床病理预后因素之间存在显著关系。需要进一步采用标准方法进行全面的前瞻性试验，以评估HER-2表达在结直肠癌患者中的作用。
